TruSight™ Oncology 500: Enabling Comprehensive Genomic Profiling for Every Laboratory
The next step in precision medicine lies in decentralizing comprehensive biomarker testing
sponsored by Illumina
In the fight against cancer, the future lies in immuno-oncology. This powerful treatment strategy bolsters the immune system's ability to target and destroy cancerous cells – but despite its promise, not all patients who undergo this treatment will benefit. Why? Because not all tumors respond equally to immunotherapy. The solution lies in leveraging biomarkers that can assist in distinguishing responders from non-responders to thereby recommend appropriate immuno-oncology approaches for patients who are likely to benefit.
Key immuno-oncology biomarkers include tumor mutational burden (TMB), which measures the number of nonsynonymous mutations within the coding region of a tumor genome as a surrogate of the likelihood of neoantigen presentation by the tumor, and microsatellite instability (MSI), a Food and Drug Administration (FDA)-approved pan-cancer biomarker that can identify tumors for treatment with immune checkpoint inhibitors. When combined with detailed mutation analysis, these markers contribute to an unprecedented level of personalization.
Read the full article now
Log in or register to read this article in full and gain access to The Pathologist’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Pathologist magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.